ClinicalTrials.gg
RecruitingNCT06879236CALIBREUpdated Sep 17, 2026

Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease

An observational study in NASH and NAFLD, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
252
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy — 21 open to participants now, 29 under way, 7 of them phase 3. Non-alcoholic Fatty Liver Disease · Italy.

Planned enrollment
10th of 24
252 · median 136
Started
2025
with 1 other
Observational
24 of 99
9 open now
Primary completion
2026-12
later than 12 of 28 live
Registered
95th of 99
by date
Lead sponsor
6 of 99
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Among the 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy, this one is the 10th largest by planned enrollment of the 24 observational ones that give a count, is one of 2 that started in 2025, is one of 24 observational ones, reaches primary completion later than 12 of the 28 other live ones, and was the 95th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

21 of the 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy, or all of them as a file.
02

Study summary

The prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, Metabolic dysfunction-associated steatohepatitis (MASH), is high and they are increasingly becoming major causes of cirrhosis, hepatocellular carcinoma (HCC), and the need for liver transplantation. Due to the lack of noticeable symptoms during the early stages, the detection of MASLD is often delayed until the disease has advanced.

Currently, the treatment options MASLD are limited to lifestyle interventions such as dietary changes and physical activity. Despite the increasing prevalence of MASLD, there are no drugs available on the market specifically for this condition.

The goal is to made new model care which integrates the standard clinical procedures with a digital approach, namely a mobile application for patients and a clinical dashboard for healthcare professionals (HCPs), integrated with simple clinical data (anthropometric, laboratory and imaging data).

This study wants to test the feasibility of integrating a digital intervention to improve the patient engagement and linkage to care in order to identify the advanced MASLD at earliest stage (secondary prevention) and mitigate the impact of ongoing advanced liver disease helping patients to manage the long-term effect of disease.

To achieve this goal the study will leverage on a mobile app named OpenTele in order to test the adherence to lifestyle changes in patient with MASLD and on the connected clinical dashboard.

The app aims at integrating the standard clinical practice with digital technologies able to guide and support patients in order to seamlessly integrate secondary prevention strategies in their everyday life with 2 main aims:

  • to implement a strategy for delay progression of liver disease;
  • to reduce the effect of cirrhosis (tertiary prevention).
03

Conditions studied

  • NASH
  • NAFLD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

subjects with type 2 diabetes and/or metabolic syndrome and/or dyslipidemia and/or obesity (BMI>30 Kg/m2) and/or familiar history for cirrhosis or liver cancer in the absence of known risk factors

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with MASLD and LSM>= 10 kPa
  • Age >= 18 years old
  • Sufficient digital literacy or supported from a caregiver with sufficient digital literacy
  • Smartphone (Android or iOS) able to download and run the App
  • Able to understand and communicate in Italian
  • Able to sign the

Exclusion criteria

Exclusion Criteria:

  • Major psychiatric disorder
  • Not able to use digital technologies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
252 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. App Adherence (>80% over 4 weeks)

    Assessed via smartphone (number of app access)

    Time frame: 4 weeks

Secondary outcomes

  1. Weight reduction assessment

    Number of subjects with a 12-month reduction between 7-10% of weight compared to baseline

    Time frame: 12 month

  2. Change in liver and spleen stiffness

    Assessed by transient elastography

    Time frame: Baseline, after 4 weeks and 12 month

  3. Change in Patient Reported Outcome questionnaire

    Evaluation of overall physical well-being through the administration of questionnaires

    Time frame: 12 weeks

  4. Changes in measure energy expenditure

    Cycle ergometer

    Time frame: 12 month

  5. Microbiome signature

    Analysis of microbiome signature from feces

    Time frame: 12 month

  6. Clinical events

    Record of number of hospitalization, decompensation, variceal bleeding, encephalopathy, ascites, liver cancer, liver transplantation, death

    Time frame: 12 month

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 160 non-industry observational studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 125. This study's planned 22 months is below that.

Counting every sponsor, half of 171 studies reached it within 49 months; a quarter within 24 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2024
First posted
Mar 17, 2025
StartActual
Jan 16, 2025
Primary completionEst.
Dec 14, 2026
CompletionEst.
Jan 1, 2028
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06879236
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Jan 16, 2025
Primary completion
Dec 14, 2026 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Sep 17, 2026

Study contacts

Luca Miele
Contact
luca.miele@policlinicogemelli.it
+390630155701
Luca Miele
principal investigator · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion